CA3085782A1 - Wnt surrogate molecules and uses thereof - Google Patents

Wnt surrogate molecules and uses thereof Download PDF

Info

Publication number
CA3085782A1
CA3085782A1 CA3085782A CA3085782A CA3085782A1 CA 3085782 A1 CA3085782 A1 CA 3085782A1 CA 3085782 A CA3085782 A CA 3085782A CA 3085782 A CA3085782 A CA 3085782A CA 3085782 A1 CA3085782 A1 CA 3085782A1
Authority
CA
Canada
Prior art keywords
fzd
binding
wnt
wnt surrogate
surrogate molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3085782A
Other languages
English (en)
French (fr)
Inventor
Yang Li
Tom Zhiye YUAN
Aaron Ken Sato
Wen-Chen Yeh
Claudia Yvonne JANDA
Tristan William FOWLER
Helene Baribault
Kuo-Pao LAI
Liqin XIE
Randall J. Brezski
Chenggang LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surrozen Operating Inc
Original Assignee
Surrozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66993916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3085782(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Surrozen Inc filed Critical Surrozen Inc
Publication of CA3085782A1 publication Critical patent/CA3085782A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CA3085782A 2017-12-19 2018-12-19 Wnt surrogate molecules and uses thereof Pending CA3085782A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762607875P 2017-12-19 2017-12-19
US62/607,875 2017-12-19
US201862641217P 2018-03-09 2018-03-09
US62/641,217 2018-03-09
US201862680522P 2018-06-04 2018-06-04
US62/680,522 2018-06-04
PCT/US2018/066616 WO2019126398A1 (en) 2017-12-19 2018-12-19 Wnt surrogate molecules and uses thereof

Publications (1)

Publication Number Publication Date
CA3085782A1 true CA3085782A1 (en) 2019-06-27

Family

ID=66993916

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3085782A Pending CA3085782A1 (en) 2017-12-19 2018-12-19 Wnt surrogate molecules and uses thereof

Country Status (7)

Country Link
US (3) US11773171B2 (https=)
EP (1) EP3732201A4 (https=)
JP (4) JP7330977B2 (https=)
CN (2) CN118271444A (https=)
AU (2) AU2018393073B2 (https=)
CA (1) CA3085782A1 (https=)
WO (1) WO2019126398A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7550647B2 (ja) * 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
CN112399973B (zh) * 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
US20210292422A1 (en) * 2018-07-05 2021-09-23 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
WO2020132356A1 (en) * 2018-12-19 2020-06-25 Surrozen, Inc. Antigen binding formats for receptor complexes
EP3924381A4 (en) * 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
US20220175884A1 (en) * 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
JP7377288B2 (ja) * 2019-06-11 2023-11-09 アントレラ セラピューティクス インコーポレイテッド 多価ｆｚｄおよびｗｎｔ結合分子とその使用
CA3144499A1 (en) 2019-07-02 2021-01-07 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
CA3170340A1 (en) * 2020-02-24 2021-09-02 Surrozen Operating, Inc. Wnt super agonists
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
CN116057185A (zh) 2020-08-15 2023-05-02 雷杰纳荣制药公司 治疗具有编码降钙素受体(calcr)的变体核酸分子的受试者的肥胖症
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
WO2022192445A1 (en) * 2021-03-10 2022-09-15 Surrozen Operating, Inc. Modulation of wnt signaling in gastrointestinal disorders
CN113403277B (zh) * 2021-06-28 2023-05-16 山东省第二人民医院(山东省耳鼻喉医院、山东省耳鼻喉研究所) 一种分离内耳fzd10阳性胶质细胞的方法
CN113651891B (zh) * 2021-08-02 2023-08-04 苏州天梯生物医药有限公司 双特性抗体在制备治疗先天性α-肌营养不良症药物中的应用
EP4457242A4 (en) * 2021-12-31 2025-12-31 Surrozen Operating Inc SPECIFIC COMPOSITE OF A WNT RECEIVER AND ASSOCIATED METHOD
US20250346681A1 (en) * 2022-04-11 2025-11-13 Astrazeneca Ab T cell binding proteins
EP4719454A2 (en) * 2023-05-29 2026-04-08 Surrozen Operating, Inc. Wnt surrogate agents and methods for lacrimal gland regeneration
CN119462916A (zh) * 2023-08-11 2025-02-18 上海科技大学 一种Wnt信号通路调节系统及激活Wnt信号通路的方法
CN117164706A (zh) * 2023-09-05 2023-12-05 中国农业科学院兰州兽医研究所 靶向塞内卡病毒a的纳米抗体筛选及其应用

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE369144T1 (de) 2000-03-31 2007-08-15 Gen Hospital Corp Verfahren zur steigerung des haarwuchses durch wnt polypeptid
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US20050169995A1 (en) 2003-10-03 2005-08-04 Kuo Calvin J. Modulation of gastrointestinal epithelium proliferation through the Wnt signaling pathway
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
JP5122278B2 (ja) 2004-05-13 2013-01-16 ユニバーシティ オブ バージニア パテント ファウンデーション 眼細胞生存の促進におけるラクリチンの使用
US8343922B2 (en) 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US7771937B2 (en) 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US20090311243A1 (en) 2005-05-30 2009-12-17 Astrazeneca Ab Methods for Identifying FZD8 Modulators and the Use of such Modulators for Treating Osteoarthritis
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AU2007212390A1 (en) 2006-02-07 2007-08-16 Wyeth Materials and methods for identifying agents that modulate Norrin, Norrin mimetics, and agents identified thereby
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
EP2386577A3 (en) 2006-06-21 2012-05-02 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
WO2008134632A1 (en) 2007-04-26 2008-11-06 President And Fellows Of Harvard College Wnt ligands involved in blood-brain barrier development and uses therefor
BRPI0820327A2 (pt) 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
EP2220247A4 (en) * 2007-11-16 2011-10-26 Nuvelo Inc ANTIBODY AGAINST LRP6
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
CN102065895A (zh) 2008-04-11 2011-05-18 比奥根艾迪克Ma公司 抗-igf-1r抗体和其它化合物的治疗联合
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
RU2547595C2 (ru) 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
SG193209A1 (en) 2008-09-10 2013-09-30 Genentech Inc Methods for inhibiting ocular angiogenesis
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
GB0819449D0 (en) 2008-10-23 2008-12-03 Cambridge Display Tech Ltd Display drivers
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
EP2393917B1 (en) 2009-02-03 2016-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells.
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US20100254979A1 (en) 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
EP2486126B1 (en) 2009-10-06 2017-12-06 SNU R & DB Foundation Method for differentiation into retinal cells from stem cells
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
CN102985441B (zh) 2010-02-19 2015-04-22 俄克拉何马大学董事会 抑制Wnt信号传导途径的单克隆抗体及其制备方法和用途
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011127164A2 (en) 2010-04-08 2011-10-13 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CA2825211A1 (en) 2011-01-28 2012-08-02 The Board Of Trustees Of The Leland Standford Junior University Wnt compositions and methods of use thereof
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
JP2014527818A (ja) * 2011-09-16 2014-10-23 フェイト セラピューティクス，インコーポレイテッド Ｗｎｔ組成物およびそのような組成物の治療的使用
WO2013054307A2 (en) 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
HUE033245T2 (hu) 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
US9200072B2 (en) 2012-01-18 2015-12-01 Genentech Inc. Anti-LRP5 antibodies and methods of use
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
WO2014059068A1 (en) 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
CN105431161A (zh) 2013-02-21 2016-03-23 范安德尔研究所 Norrin突变体多肽、其制造方法和用途
US20140255403A1 (en) 2013-03-06 2014-09-11 Hadasit Medical Research Services & Development Ltd. Oral composition comprising a tnf antagonist and use thereof
CA2900955A1 (en) 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
EP2968452A4 (en) 2013-03-15 2016-10-05 Michael Thomas Trese COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
CA2906737C (en) 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
AU2015314771B2 (en) 2014-09-12 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016168607A1 (en) 2015-04-15 2016-10-20 University Of Tennessee Research Foundation Compositions and methods of muc13 antibodies for cancer treatment and diagnosis
US20160312207A1 (en) 2015-04-21 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
WO2016205551A2 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SG11201803061UA (en) 2015-10-21 2018-05-30 Univ Indiana Res & Tech Corp Methods of generating human inner ear sensory epithelia and sensory neurons
UA122079C2 (uk) 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
WO2017127933A1 (en) 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
US11421028B2 (en) 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CA3014659A1 (en) 2016-03-02 2017-09-08 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
US20170349659A1 (en) 2016-06-03 2017-12-07 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3630816B1 (en) 2017-05-31 2024-03-20 Boehringer Ingelheim International GmbH Polypeptides antagonizing wnt signaling in tumor cells
CA3081854A1 (en) 2017-11-08 2019-05-16 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to cd40 and epcam
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
JP7550647B2 (ja) 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
IL277307B2 (en) 2018-03-23 2025-03-01 Univ Bruxelles Wnt signaling agonist molecules
US20210292422A1 (en) 2018-07-05 2021-09-23 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3823661A4 (en) 2018-07-16 2022-05-11 The Board of Trustees of the Leland Stanford Junior University SPECIFIC FRIZZLED WNT AGONISTS AND ANTAGONISTS
WO2020132356A1 (en) 2018-12-19 2020-06-25 Surrozen, Inc. Antigen binding formats for receptor complexes
EP3924381A4 (en) 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
EP3938036A4 (en) 2019-03-11 2023-06-28 Surrozen Operating, Inc. Modulation of wnt signaling in gastrointestinal disorders
US20220175884A1 (en) 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
US11050604B2 (en) 2019-07-01 2021-06-29 Rampart Communications, Inc. Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
CA3144499A1 (en) 2019-07-02 2021-01-07 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
WO2021173712A1 (en) 2020-02-24 2021-09-02 The Board Of Regents Of The University Of Texas System Molecular biomarkers and targets for fuchs' endothelial corneal dystrophy and glaucoma
CA3170340A1 (en) 2020-02-24 2021-09-02 Surrozen Operating, Inc. Wnt super agonists
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
CA3204321A1 (en) 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2022192445A1 (en) 2021-03-10 2022-09-15 Surrozen Operating, Inc. Modulation of wnt signaling in gastrointestinal disorders
JP7575616B2 (ja) 2021-07-20 2024-10-29 ボストン サイエンティフィック メディカル デバイス リミテッド 再配置可能なオーバーザスコープクリップ
CA3229303A1 (en) 2021-09-14 2023-03-23 Russell FLETCHER Modulation of wnt signalling in pulmonary disorders
AU2022413699A1 (en) 2021-12-17 2024-07-04 Surrozen Operating, Inc. Wnt-surrogate agents and methods for lacrimal gland regeneration
EP4457242A4 (en) 2021-12-31 2025-12-31 Surrozen Operating Inc SPECIFIC COMPOSITE OF A WNT RECEIVER AND ASSOCIATED METHOD
JP2025525362A (ja) 2022-06-21 2025-08-05 スロゼン オペレーティング， インコーポレイテッド 角膜障害におけるｗｎｔシグナル伝達の調節
WO2024040118A2 (en) 2022-08-16 2024-02-22 Surrozen Operating, Inc. Cell targeting multicomponent polypeptide
US20240262918A1 (en) 2022-12-30 2024-08-08 Surrozen Operating, Inc. Fc-modified wnt surrogate molecules and uses thereof
EP4719454A2 (en) 2023-05-29 2026-04-08 Surrozen Operating, Inc. Wnt surrogate agents and methods for lacrimal gland regeneration

Also Published As

Publication number Publication date
US20240141049A1 (en) 2024-05-02
JP7604560B2 (ja) 2024-12-23
US20250223368A1 (en) 2025-07-10
US11773171B2 (en) 2023-10-03
AU2025283437A1 (en) 2026-03-12
JP2025176086A (ja) 2025-12-03
JP2021506297A (ja) 2021-02-22
JP2024057106A (ja) 2024-04-23
CN118271444A (zh) 2024-07-02
AU2018393073A1 (en) 2020-07-02
CN111727203A (zh) 2020-09-29
JP7737494B2 (ja) 2025-09-10
US12297278B2 (en) 2025-05-13
EP3732201A4 (en) 2022-04-20
WO2019126398A1 (en) 2019-06-27
JP7330977B2 (ja) 2023-08-22
EP3732201A1 (en) 2020-11-04
CN111727203B (zh) 2024-04-26
AU2018393073B2 (en) 2025-09-18
US20200308287A1 (en) 2020-10-01
JP2023113950A (ja) 2023-08-16

Similar Documents

Publication Publication Date Title
US12297278B2 (en) Wnt surrogate molecules and uses thereof
CN112566940B (zh) 多特异性wnt替代分子和其用途
JP7667823B2 (ja) 抗ｌｒｐ５／６抗体及び使用方法
US12606629B2 (en) Monospecific anti-frizzled antibodies and methods of use
US20240262918A1 (en) Fc-modified wnt surrogate molecules and uses thereof
WO2026044275A1 (en) Wnt surrogate fusion molecule
WO2026044271A1 (en) Wnt surrogate fusion molecule
WO2026044274A1 (en) Wnt surrogate fusion molecule

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220914

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241213

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250606

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250609